About HEPALINK Company

Established in Shenzhen in 1998, Hyperpree is a leading multinational pharmaceutical company with an A+H dual financing platform. Its main business covers the heparin industry chain, biomacromolecule contract development and production organization (“CDMO”), and investment, development and commercialization of innovative drugs. The Group's three business segments collaborate with each other, driven by unmet clinical needs, and are committed to providing high-quality, safe and effective drugs and services to patients around the world to protect their health. The Group's business scope covers pharmaceutical production and sales, CDMO services and innovative drug development. The drugs we sell include (i) pharmaceutical preparations (mainly including enoxaparin sodium injections); (ii) API products (mainly including heparin sodium API and enoxaparin sodium API); and (iii) other products (mainly including pancreatin API). In the field of the heparin industry chain, Hypry is one of the industry and market leaders. The Group's enoxaparin sodium preparations are currently sold to more than 40 countries around the world. Since being approved by the European Medicines Agency (“EMA”) through the Centralized Approval Procedure (CP) in 2016, it has been among the top domestic companies in the same industry due to its excellent product quality and stable efficacy; and passed the consistent evaluation of generic drug quality and efficacy by the China National Drug Administration in October 2020. The Group is the first supplier of enoxaparin sodium formulations in China to be reviewed. We operate the CDMO business through our wholly-owned subsidiary Cytovance Biologics, Inc. (“Saiwan Biotech”), which specializes in the development and production of recombinant drugs and critical non-viral vectors and gene therapy intermediates, and through our wholly-owned subsidiary SPL Acquisition Corp. (“SPL”) (which provides services for the development and production of naturally derived drugs), providing research and development (“R&D”), production, quality management and process management services. The Group has obtained exclusive development and commercialization rights for several clinical-stage innovative drug candidates in the People's Republic of China (“China”), and we are developing these drugs to treat diseases related to the immune system axis. We are also developing a proprietary drug candidate developed independently by us, which is currently in the pre-clinical phase.